{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T19:56:23Z","timestamp":1787860583672,"version":"build-2784847793"},"reference-count":56,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["821520"],"award-info":[{"award-number":["821520"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013322","name":"European Federation of Pharmaceutical Industries and Associations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.therap.2024.10.049","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T15:43:45Z","timestamp":1729266225000},"page":"378-416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Systematic review of gabapentinoid use during pregnancy and its impact on pregnancy and childhood outcomes: A ConcePTION study"],"prefix":"10.1016","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4631-100X","authenticated-orcid":false,"given":"Anna-Belle","family":"Beau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingping","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Moisset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"B\u00e9n\u00e9vent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Damase-Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2024.10.049_bib0285","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.reprotox.2016.11.002","article-title":"Involvement of l-type amino acid transporter 1 in the transport of gabapentin into human placental choriocarcinoma cells","volume":"67","author":"Furugen","year":"2017","journal-title":"Reprod Toxicol"},{"key":"10.1016\/j.therap.2024.10.049_bib0290","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1111\/j.1528-1167.2005.00251.x","article-title":"Pharmacokinetics of gabapentin during delivery, in the neonatal period, and lactation: does a fetal accumulation occur during pregnancy?","volume":"46","author":"Ohman","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.therap.2024.10.049_bib0295","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1001\/jamainternmed.2017.7856","article-title":"Gabapentinoid use in the United States 2002 through 2015","volume":"178","author":"Johansen","year":"2018","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.therap.2024.10.049_bib0300","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1001\/jama.2018.12358","article-title":"Trends in first gabapentin and pregabalin prescriptions in primary care in the United Kingdom, 1993\u20132017","volume":"320","author":"Montastruc","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.therap.2024.10.049_bib0305","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMp1704633","article-title":"Gabapentin and pregabalin for pain\u00a0\u2013\u00a0Is increased prescribing a cause for concern?","volume":"377","author":"Goodman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2024.10.049_bib0310","doi-asserted-by":"crossref","first-page":"e1083","DOI":"10.1212\/WNL.0000000000207580","article-title":"Utilization of antiseizure medications in women of childbearing age with epilepsy and nonepilepsy indications: a retrospective cohort study","volume":"101","author":"Lawal","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.therap.2024.10.049_bib0315","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1002\/pds.4897","article-title":"Prescription of antiepileptic medicines including valproate in pregnant women: a study in three European countries","volume":"28","author":"Hurault-Delarue","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.therap.2024.10.049_bib0320","first-page":"47","article-title":"Teratogenic effects of the anticonvulsant gabapentin in mice","volume":"49","author":"Prakash","year":"2008","journal-title":"Singapore Med J"},{"key":"10.1016\/j.therap.2024.10.049_bib0325","series-title":"Summary of the European public assessment report: neurontin gabapentin","year":"2006"},{"key":"10.1016\/j.therap.2024.10.049_bib0330","first-page":"1065","article-title":"Teratogenic effects of pregabalin in mice","volume":"16","author":"Etemad","year":"2013","journal-title":"Iran J Basic Med Sci"},{"key":"10.1016\/j.therap.2024.10.049_bib0335","series-title":"Summary of the European public assessment report: lyrica pregabalin","year":"2022"},{"key":"10.1016\/j.therap.2024.10.049_bib0340","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/bcp.15607","article-title":"A critical appraisal of controlled studies investigating malformation risks following pregabalin use in early pregnancy","volume":"89","author":"Richardson","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.049_bib0345","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1007\/s00228-022-03384-1","article-title":"Neonatal outcomes after gamma-aminobutyric acid analog use during pregnancy: a meta-analysis of cohort studies","volume":"78","author":"Jin","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.049_bib0350","doi-asserted-by":"crossref","first-page":"o1010","DOI":"10.1136\/bmj.o1010","article-title":"Avoid prescribing pregabalin during pregnancy if possible, says UK drug regulator","volume":"377","author":"Wise","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.therap.2024.10.049_bib0355","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.therap.2024.10.049_bib0360","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.therap.2024.10.049_bib0365","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1111\/bcp.15053","article-title":"Changes in antiepileptic drug prescriptions over a decade in childbearing women in Lombardy region, Italy","volume":"88","author":"Clavenna","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.049_bib0370","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1212\/WNL.0b013e31828f18c1","article-title":"Pregnancy outcomes following gabapentin use: results of a prospective comparative cohort study","volume":"80","author":"Fujii","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.therap.2024.10.049_bib0375","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/bdra.23028","article-title":"Newer anticonvulsants: lamotrigine, topiramate and gabapentin","volume":"94","author":"Holmes","year":"2012","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"10.1016\/j.therap.2024.10.049_bib0380","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.eplepsyres.2018.11.010","article-title":"Antiepileptic drug treatment during pregnancy and delivery in women with epilepsy \u2013 A retrospective single center study","volume":"149","author":"Shihman","year":"2019","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.therap.2024.10.049_bib0385","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1479-828X.2007.00781.x","article-title":"The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies","volume":"47","author":"Vajda","year":"2007","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"10.1016\/j.therap.2024.10.049_bib0390","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.seizure.2010.07.019","article-title":"Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register","volume":"19","author":"Vajda","year":"2010","journal-title":"Seizure"},{"key":"10.1016\/j.therap.2024.10.049_bib0395","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/ana.25031","article-title":"Fetal growth and premature delivery in pregnant women on antiepileptic drugs","volume":"82","author":"Hern\u00e1ndez-D\u00edaz","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1016\/j.therap.2024.10.049_bib0400","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1136\/jnnp-2017-316143","article-title":"Adverse pregnancy outcomes in women exposed to gabapentin and pregabalin: data from a population-based study","volume":"89","author":"Mostacci","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.therap.2024.10.049_bib0405","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.jocn.2013.11.049","article-title":"The Australian Register of Antiepileptic Drugs in Pregnancy: changes over time in the epileptic population","volume":"21","author":"Vajda","year":"2014","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.therap.2024.10.049_bib0410","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/ane.12280","article-title":"The teratogenicity of the newer antiepileptic drugs\u00a0\u2013\u00a0an update","volume":"130","author":"Vajda","year":"2014","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.therap.2024.10.049_bib0415","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/ane.12672","article-title":"Antiepileptic drugs, foetal malformations and spontaneous abortions","volume":"135","author":"Vajda","year":"2017","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.therap.2024.10.049_bib0420","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1212\/WNL.0000000000002767","article-title":"Pregnancy outcome following maternal exposure to pregabalin may call for concern","volume":"86","author":"Winterfeld","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.therap.2024.10.049_bib0425","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1525-5050(03)00110-0","article-title":"Gabapentin exposure in human pregnancy: results from the Gabapentin Pregnancy Registry","volume":"4","author":"Montouris","year":"2003","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.therap.2024.10.049_bib0430","doi-asserted-by":"crossref","first-page":"e1003322","DOI":"10.1371\/journal.pmed.1003322","article-title":"Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: a population-based cohort study nested in the US Medicaid Analytic eXtract dataset","volume":"17","author":"Patorno","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.therap.2024.10.049_bib0435","doi-asserted-by":"crossref","first-page":"871136","DOI":"10.3389\/fphar.2022.871136","article-title":"Trends of utilization of antiseizure medications among pregnant women in Manitoba, Canada: a 20-year population-based study","volume":"13","author":"Shouman","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.therap.2024.10.049_bib0440","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/ppe.13086","article-title":"Risks of congenital malformations and neonatal intensive care unit admissions with gabapentin use in pregnancy: a cohort study and scoping review with meta-analysis","volume":"38","author":"Desrochers","year":"2024","journal-title":"Paediatr Perinat Epidemiol"},{"key":"10.1016\/j.therap.2024.10.049_bib0445","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/pds.4556","article-title":"Development of an algorithm to identify pregnancy episodes and related outcomes in health care claims databases: an application to antiepileptic drug use in 4.9 million pregnant women in France","volume":"27","author":"Bloti\u00e8re","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.therap.2024.10.049_bib0450","doi-asserted-by":"crossref","first-page":"w20386","DOI":"10.4414\/smw.2021.20386","article-title":"Use of valproate in pregnancy and in women of childbearing age between 2014 and 2018 in Switzerland: a retrospective analysis of Swiss healthcare claims data","volume":"151","author":"Spoendlin","year":"2021","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.therap.2024.10.049_bib0455","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12884-018-1728-y","article-title":"Antiepileptic drug exposure in pregnancy and pregnancy outcome from national drug usage data","volume":"18","author":"Richards","year":"2018","journal-title":"BMC Pregnancy Childbirth"},{"key":"10.1016\/j.therap.2024.10.049_bib0460","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.3390\/ph6101221","article-title":"The use of central nervous system active drugs during pregnancy","volume":"6","author":"K\u00e4ll\u00e9n","year":"2013","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.therap.2024.10.049_bib0465","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00415-013-7239-x","article-title":"Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy","volume":"261","author":"Veiby","year":"2014","journal-title":"J Neurol"},{"key":"10.1016\/j.therap.2024.10.049_bib0470","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1212\/WNL.0000000000003959","article-title":"Pregabalin use early in pregnancy and the risk of major congenital malformations","volume":"88","author":"Patorno","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.therap.2024.10.049_bib0475","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s40264-023-01307-2","article-title":"Prenatal exposure to pregabalin, birth outcomes and neurodevelopment\u00a0\u2013\u00a0a population-based cohort study in four Nordic countries","volume":"46","author":"Dudukina","year":"2023","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2024.10.049_bib0480","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1212\/WNL.0000000000007696","article-title":"Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs","volume":"93","author":"Bloti\u00e8re","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.therap.2024.10.049_bib0485","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1001\/jama.2011.624","article-title":"Newer-generation antiepileptic drugs and the risk of major birth defects","volume":"305","author":"M\u00f8lgaard-Nielsen","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.therap.2024.10.049_bib0490","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/jnnp.2005.074203","article-title":"Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register","volume":"77","author":"Morrow","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.therap.2024.10.049_bib0495","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1111\/epi.12758","article-title":"Birth outcomes after prenatal exposure to antiepileptic drugs\u00a0\u2013\u00a0a population-based study","volume":"55","author":"Kilic","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.therap.2024.10.049_bib0500","doi-asserted-by":"crossref","first-page":"e0214180","DOI":"10.1371\/journal.pone.0214180","article-title":"Relation of in-utero exposure to antiepileptic drugs to pregnancy duration and size at birth","volume":"14","author":"Margulis","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.therap.2024.10.049_bib0505","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1136\/jnnp-2023-333149","article-title":"First-trimester use of antiseizure medications and the risk of miscarriage: a population-based cohort study","volume":"95","author":"Forbes","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.therap.2024.10.049_bib0510","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.seizure.2009.09.002","article-title":"Population-based study of antiepileptic drug exposure in utero\u00a0\u2013\u00a0influence on head circumference in newborns","volume":"18","author":"Almgren","year":"2009","journal-title":"Seizure"},{"key":"10.1016\/j.therap.2024.10.049_bib0515","doi-asserted-by":"crossref","first-page":"100849","DOI":"10.1016\/j.lanepe.2024.100849","article-title":"Prenatal exposure to antiseizure medications and fetal growth: a population-based cohort study from the Nordic countries","volume":"38","author":"Christensen","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.therap.2024.10.049_bib0520","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/jamaneurol.2022.1269","article-title":"Association of prenatal exposure to antiseizure medication with risk of autism and intellectual disability","volume":"79","author":"Bj\u00f8rk","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.therap.2024.10.049_bib0525","doi-asserted-by":"crossref","first-page":"e034829","DOI":"10.1136\/bmjopen-2019-034829","article-title":"Risk of early neurodevelopmental outcomes associated with prenatal exposure to the antiepileptic drugs most commonly used during pregnancy: a French nationwide population-based cohort study","volume":"10","author":"Bloti\u00e8re","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.therap.2024.10.049_bib0530","doi-asserted-by":"crossref","first-page":"17362","DOI":"10.1038\/s41598-020-74409-x","article-title":"Risk of early neurodevelopmental disorders associated with in utero exposure to valproate and other antiepileptic drugs: a nationwide cohort study in France","volume":"10","author":"Coste","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.therap.2024.10.049_bib0535","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1001\/jamaneurol.2023.0674","article-title":"Prenatal exposure to antiseizure medication and incidence of childhood- and adolescence-onset psychiatric disorders","volume":"80","author":"Dreier","year":"2023","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.therap.2024.10.049_bib0540","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1136\/jnnp-2018-318386","article-title":"In utero exposure to antiepileptic drugs is associated with learning disabilities among offspring","volume":"89","author":"Bech","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.therap.2024.10.049_bib0545","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/ppe.12004","article-title":"Trends in the use of antiepileptic drugs among pregnant women in the US, 2001\u20132007: a medication exposure in pregnancy risk evaluation program study","volume":"26","author":"Bobo","year":"2012","journal-title":"Paediatr Perinat Epidemiol"},{"key":"10.1016\/j.therap.2024.10.049_bib0550","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1001\/jama.2011.624","article-title":"Newer-generation antiepileptic drugs and the risk of major birth defects","volume":"305","author":"M\u00f8lgaard-Nielsen","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.therap.2024.10.049_bib0555","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/jnnp-2017-317833","article-title":"Emilia-Romagna Study on Pregnancy and Exposure to Antiepileptic drugs (ESPEA): a population-based study on prescription patterns, pregnancy outcomes and fetal health","volume":"89","author":"Mostacci","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.therap.2024.10.049_bib0560","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1651-2227.2004.tb00701.x","article-title":"Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study","volume":"93","author":"Wide","year":"2004","journal-title":"Acta Paediatr"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595724001653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595724001653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T01:47:24Z","timestamp":1762220844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595724001653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0040595724001653"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2024.10.049","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic review of gabapentinoid use during pregnancy and its impact on pregnancy and childhood outcomes: A ConcePTION study","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2024.10.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique.","name":"copyright","label":"Copyright"}]}}